Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

Interim data from two investigator-initiated trials (IITs) supported by Galderma highlight the effectiveness of Sculptra® and Restylane® in addressing aesthetic changes due to menopause and weight loss medications. The trials showed significant improvements in skin hydration and quality, particularly when Restylane Skinboosters were used first. The findings emphasize the need for regenerative aesthetic treatments in managing skin changes associated with menopause and medication-driven weight loss, reinforcing Galderma's commitment to supporting independent research and patient needs.